Shots:
- The EC has approved Cabometyx for inoperable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET) & extra-pancreatic NET (epNET) pts, who progressed on ≥1 prior systemic therapy other than somatostatin analogues in all 30 EEA states
- Approval was based on P-III (CABINET) study assessing Cabometyx (60mg) vs PBO among 298 US pts, which were randomized into 2 arms (pNET & epNET)
- Trial was stopped early after interim analysis & showed superior efficacy, with significant & clinically meaningful improvement in PFS; results were presented at ESMO 2024 & published in The NEJM
Ref: Exelixis | Image: Exelixis & Ipsen| Press Release
Related News:- Ipsen Reports P-II (ELMWOOD) Trial Data of Elafibranor for Primary Sclerosing Cholangitis (PSC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
